Statement: the primary clinical trial provides data on the proportion of patients receiving combined treatment of neratinib and paclitaxel who encounter serious enough side effects that obstruct an escalation in treatment dose or intensity.
Primary_evidence: Outcome Measurement:    Dose Limiting Toxicity Incidence of Neratinib in Combination With Paclitaxel   Dose Limiting Toxicity in subjects with solid tumors treated with neratinib, administered daily, in combination with paclitaxel 80 mg/m² IV on days 1, 8, and 15 of a 28 day cycle.   Time frame: From first dose date through day 28 Results 1:    Arm/Group Title: Neratinib 160 mg + Paclitaxel 80 mg/m    Arm/Group Description: Neratinib 160 mg qd + Paclitaxel 80 mg/m  IV on days 1, 8, and 15 of a 28 day cycle.   Overall Number of Participants Analyzed: 3   Measure Type: Count of Participants   Unit of Measure: Participants  0   0.0% Results 2:    Arm/Group Title: Neratinib 240 mg + Paclitaxel 80 mg/m    Arm/Group Description: Neratinib 240 mg qd + Paclitaxel 80 mg/m  IV on days 1, 8, and 15 of a 28 day cycle.   Overall Number of Participants Analyzed: 5   Measure Type: Count of Participants   Unit of Measure: Participants  0   0.0%